Oak Grove Capital LLC purchased a new position in Gilead Sciences (NASDAQ:GILD) during the fourth quarter, Holdings Channel reports. The firm purchased 28,475 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Gilead Sciences accounts for approximately 2.1% of Oak Grove Capital LLC’s portfolio, making the stock its 14th biggest holding.
A number of other institutional investors have also recently made changes to their positions in GILD. Williams Jones & Associates LLC lifted its stake in Gilead Sciences by 10.4% during the 2nd quarter. Williams Jones & Associates LLC now owns 6,930 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 650 shares during the period. Prudential PLC lifted its stake in Gilead Sciences by 5.0% during the 2nd quarter. Prudential PLC now owns 3,525,167 shares of the biopharmaceutical company’s stock valued at $249,512,000 after acquiring an additional 168,200 shares during the period. Sii Investments Inc. WI lifted its stake in Gilead Sciences by 13.3% during the 2nd quarter. Sii Investments Inc. WI now owns 34,727 shares of the biopharmaceutical company’s stock valued at $2,460,000 after acquiring an additional 4,083 shares during the period. San Francisco Sentry Investment Group CA lifted its stake in Gilead Sciences by 9.1% during the 2nd quarter. San Francisco Sentry Investment Group CA now owns 7,094 shares of the biopharmaceutical company’s stock valued at $502,000 after acquiring an additional 593 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in Gilead Sciences by 856.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,751,194 shares of the biopharmaceutical company’s stock valued at $123,949,000 after acquiring an additional 1,568,191 shares during the period. Institutional investors own 77.91% of the company’s stock.
Gilead Sciences stock opened at $73.41 on Friday. The company has a market capitalization of $97,554.05, a P/E ratio of 8.76, a PEG ratio of -1.72 and a beta of 1.19. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
In other Gilead Sciences news, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $224,376,112.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 426,934 shares of company stock valued at $33,847,101. Insiders own 1.30% of the company’s stock.
GILD has been the topic of several research analyst reports. Maxim Group set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, December 14th. Credit Suisse Group cut shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and upped their target price for the company from $74.35 to $80.00 in a research note on Wednesday, December 20th. Oppenheimer reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, December 21st. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $88.61.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3337655/28475-shares-in-gilead-sciences-gild-purchased-by-oak-grove-capital-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
